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Abstract
The increased survival among very low birth weight (VLBW) contributes to 
the overall increase in the incidence of chronic lung disease (CLD), also known 
as bronchopulmonary dysplasia (BPD), that remains a major complication of 
prematurity.
The long-term health consequences of BPD include early and long term 
respiratory disease, susceptibility to respiratory infections, pulmonary 
hypertension, repeated hospitalizations, neurodevelopmental impairment and 
increased mortality.
BPD pathogenesis is multifactorial and includes exposure to mechanical 
ventilation, oxygen toxicity, infection, and inflammation, but the real causes in 
single individuals have not been well clarified. 
In this review the current and potential future postnatal pharmacological 
(caffeine, diuretics, postnatal corticosteroids, bronchodilators, pulmonary 
vasodilators, anti-oxidants) and non-pharmacological  strategies (ventilatory 
support, stem cells) in the prevention and management of BPD will be presented.
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Introduction
Mortality rates among very low birth weight 
(VLBW) infants have declined due to advances 
in perinatal care but the increased survival among 
these infants contributes to the overall increase in 
the incidence of chronic lung disease (CLD), also 
known as bronchopulmonary dysplasia (BPD), that 
remains a major complication of prematurity [1].
The long-term health consequences of BPD 
include respiratory disease that can persist into 
adulthood and increased susceptibility to respiratory 
infections, pulmonary hypertension, repeated 
hospitalizations, neurodevelopmental impairment 
and increased mortality [2].
BPD pathogenesis is multifactorial and includes 
exposure to mechanical ventilation, oxygen toxicity, 
infection, and inflammation [3]. Multiple pharma- 
cological and non-pharmacological approaches 
have been proposed for the prevention or treatment 
of preterm lung injury and BPD [4]. 
Most current therapeutic measures such 
as antenatal steroids, surfactant, protective 
ventilation strategies, targeted oxygen saturation 
goals, optimization of nutrition have helped to 
modestly improve BPD though they continue to be 
supportive [5].
In this review the current and potential future 
postnatal pharmacological and non-pharmacological 
strategies in the prevention and management of 
BPD will be presented.
Pharmacological strategies
Caffeine
Caffeine is a methylxantine used for treatment of 
apnea of prematurity.
The CAP trial has provided unequivocal evidence 
for the beneficial effects of caffeine on BPD [6]. 
In this trial preterm infants with birth weight 500-
1,250 g, were randomized to caffeine or placebo 
within the first 10 days of life. In the caffeine 
group compared to the placebo group, a significant 
reduction in BPD at 36 weeks PMA and a reduction 
in days of mechanical ventilation, were shown. In 
the long-term follow-up, a reduced incidence of 
cerebral palsy and neurodevelopmental disability in 
caffeine-treated group was observed [7].
Although the potential mechanism of the effect 
of caffeine on decreased incidence of BPD remains 
unknown, caffeine treatment for prevention of 
BPD is currently standard of care in most neonatal 
intensive care units (NICUs). 
Diuretics
Diuretics are used in the management of 
BPD, complicated by interstitial alveolar edema. 
Excessive fluid administration, capillary leak from 
inflammation related to infection or lung injury, 
volume overload due to a patent ductus arteriosus, 
are all factors contributing to pulmonary edema 
[8]. Furosemide, the most widely administered 
loop diuretic in newborns, can improve lung 
mechanics, increases local prostaglandin leading 
to pulmonary vasodilation, enhances lung fluid 
absorption, inhibits bronchial smooth muscle 
contraction, and decreases inflammatory mediator 
release. These potential benefits must be balanced 
against important systemic side effects including 
electrolyte disturbances, ototoxicity, and renal 
calcium excretion. Although they are used to treat 
the symptoms of BPD, there is little evidence 
of their effectiveness in improving long-term 
outcomes. A systematic review found that although 
furosemide improves pulmonary compliance, 
minute ventilation, and oxygen requirement in 
infants aged > 3 weeks with BPD, there was no 
beneficial effect in duration of oxygen requirement 
or mechanical ventilation [9].
Diuretics acting primarily at the distal tubules, 
including thiazides and spironolactone, are less 
potent than loop diuretics but potentially cause 
fewer electrolyte abnormalities. A systematic 
review showed that thiazide and spironolactone 
improved lung compliance and decreased 
intermittent furosemide; there is little evidence that 
distal diuretic administration reduces duration of 
ventilation or length of stay [10]. 
Despite a lack of evidence to support long-term 
diuretic use, such use is a routine occurrence in 
NICUs [11].
Postnatal corticosteroids
Given that inflammation plays a key role 
in the pathogenesis of BPD, corticosteroid use 
makes physiologic sense mainly due to their anti-
inflammatory properties. 
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Both systemic and inhaled corticosteroids have 
been studied extensively in preterm neonates for 
prevention and treatment of BPD. These clinical 
trials can be classified as early (≤ 7 days) and late (> 
7 days) depending on the timing of administration 
after birth.
The Cochrane meta-analysis review of twenty-
eight clinical trials of early systemic steroids 
revealed that they facilitated extubation and 
decreased the incidence of BPD. These benefits do 
not outweigh the known or potential adverse effects 
of this treatment (gastrointestinal perforation and 
cerebral palsy), and it cannot be recommended for 
routine clinical practice [12].
Another Cochrane meta-analysis reviewed the 
use of steroids at > 7 days in nineteen RCTs. The 
benefits of late dexamethasone, including reduction 
of BPD, may not outweigh actual or potential 
adverse effects [13]. Both the early and late steroid 
trials mainly used dexamethasone at high doses (> 
0.5-1 mg/kg/day).
Given the available evidence, the early use 
of dexamethasone in the first week of life is not 
indicated and it appears prudent to reserve the use 
of late dexamethasone to infants in whom weaning 
from high ventilator settings and oxygen support 
is unsuccessful or respiratory status is rapidly 
deteriorating [14]. Due to the observed side effects 
of dexamethasone, hydrocortisone effect has been 
studied for the prevention of BPD. Although no 
study showed a clear benefit with hydrocortisone 
administration, a trend towards decreased mortality 
and increased survival without BPD was observed 
in a large clinical trial on preterm infants exposed 
prenatally to chorioamnionitis [15]. A meta-analysis 
of the available randomized trials (first week of 
life) showed little evidence for a direct effect of 
hydrocortisone on the rates of BPD or mortality. 
Hydrocortisone in the doses used in the these trials 
has few beneficial and harmful effects (an increase 
in gastrointestinal perforation) and cannot be 
recommended for prevention of BPD [16]. 
Bronchodilators
Bronchodilators may be indicated in BPD due 
to increased airway resistance, smooth muscle 
hypertrophy and hyperreactivity. The two most widely 
used bronchodilators are salbutamol and ipratoprium.
Short-term studies demonstrated increased 
respiratory compliance and reduced resistance after 
bronchodilator treatment in infants with established 
and evolving BPD [17]. Although these medications 
target important components of the disease process, 
studies have shown that responses are variable and 
often transient. In conclusion, based on current 
evidence, routine use of bronchodilators for 
prevention of BPD cannot be recommended.
Pulmonary vasodilators
Pulmonary hypertension is increasingly 
recognized as a complication of premature birth 
and BPD. BPD-associated pulmonary hypertension 
is estimated to occur in 30-45% of infants with 
moderate to severe BPD and can contribute to the 
severity and persistence of BPD symptoms and 
impose additional morbidity and mortality [18]. 
Animal studies have shown that inhaled nitric 
oxide (iNO) reduces lung inflammation, improves 
surfactant function and promotes lung and alveolar 
growth, suggesting that iNO may be beneficial to 
prevent or treat BPD [19].
The role of nitric oxide (NO) in preterm infants 
regarding survival and rate of BPD is controversial. 
Early use of low-dose iNO in very premature 
infants did not improve survival without BPD or 
brain injury, and is thus unsuccessful [20]. Early 
rescue treatment (< 3 days) with iNO, based on 
oxygenation criteria, did not seem to affect mortality 
or BPD rates. Later treatment (> 3 days) based on 
the risk of BPD showed no effect on the combined 
outcome of death or BPD. Early routine use for 
intubated, mildly sick preterm infants showed only 
a small reduction in the incidence of the combined 
outcome of death or BPD [21].
In a systematic review a modest reduction in 
composite outcome of death or BPD was found but 
there was no reduction in rates of death alone or BPD 
in infants treated with iNO compared to controls. 
According to the NIH Consensus Statement, the 
current available evidence does not support the use 
of iNO, in care of premature infants, to reduce the 
occurrence or severity of BPD [22]. 
Sildenafil is a selective cyclic guanosine 
monophosphate (cGMP) specific phosphodiesterase 
inhibitor that results in increased cGMP levels 
and ultimately increased pulmonary vasodilation. 
Sildenafil is gaining attention as a potentially useful 
therapy in infants with oxygenation impairment due 
to severe BPD or pulmonary hypertension (PH). 
Animal studies have shown that sildenafil improves 
alveolar growth and reduces pulmonary hypertension, 
but there are no available clinical data of this therapy 
on newborns [23]. Sildenafil citrate should be used 
cautiously in infants with BPD-associated PH as a 
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rescue therapy, even with the possibility of longer-
term benefits of sildenafil citrate on lung growth [24]. 
Anti-oxidants
Free radicals are involved in the pathogenesis of 
BPD and preterm infants have very high susceptibility 
to oxidative stress because of their deficiency in 
endogenous antioxidant systems. 
Vitamin A is a retinoid essential for normal lung 
growth and important in regulation of lung epithelial 
cells repair. Preterm infants are relatively deficient in 
vitamin A and this has been shown to be associated 
with BPD. A Cochrane meta-analysis reviewed eight 
studies on the efficacy of intramuscular vitamin A 
supplementation in prevention of BPD in ELBW 
infants, showing a decrease in BPD rate in treated 
population [25]. The current evidence supports 
the use of high dose intramuscular vitamin A 
supplementation for the prevention of BPD in preterm 
infants < 1,000 g, although no long-term benefits in 
pulmonary or neuro-developmental outcome were 
found [26].
Vitamin E and vitamin C both play a role as 
scavengers of reactive oxygen species producted 
during high oxygen exposure and they prevent lipid 
peroxidation, potentially limiting the processes that 
lead to BPD. RCTs have showed no evidence that 
vitamin E supplementation alone or associated to 
vitamin C have a protective effect against BPD 
[27]. Preliminary animal and human studies have 
demonstrated a protective effect of anti-oxidants like 
superoxide dismutase (SOD) in hyperoxia-induced 
acute and chronic lung injury [28]. A RCT evaluated 
pulmonary outcome at 1 year in premature infants 
treated with recumbinant SOD. No difference was 
found in BPD at 28 days of life or 36 weeks PMA 
in treatment group compared to the placebo [29]. 
Gluthatione is an endogenous scavenger of free 
radicals, relatively deficient in premature infants 
with decreasing gestational age. N-Acetyl Cysteine 
(NAC) is a gluthatione precursor, potentially capable 
to ameliorate cellular injury from free radicals. No 
significant results in terms of difference of incidence 
or severity of BPD were found in preterm infants 
treated with NAC [30].
Non-pharmacological strategies
Ventilatory support
Mechanical ventilation is an important risk factor 
in the pathogenesis of BPD and lung protective 
ventilation remains an important intervention in 
the prevention of BPD. Optimization of neonatal 
respiratory support starts during the resuscitation 
period and a protective strategy is achieved through 
the definition of adequate oxygenation ranges and 
tailored ventilation [31]. 
In mechanical ventilation, the volume targeted 
ventilation had reduced death or BPD compared 
with pressure-limited ventilation and is associated 
with a reduced risk of pneumothorax, hypocarbia, 
duration of ventilation and severe intraventricular 
hemorrhage [32].
Since BPD currently has no specific preventive 
or effective therapy, considerable interest has 
focused on the use of non-invasive ventilation 
(NIV) as a means to potentially decrease the 
incidence of BPD [33].
Over the last decade, nasal continuous positive 
airway pressure (NCPAP) has been increasingly 
used to manage preterm infants in the delivery room 
and in the neonatal intensive care unit as primary 
treatment of RDS or post-extubation [34]. Anecdotal 
evidence and small RCTs have suggested that early 
NCPAP use could lead to a decreased incidence of 
BPD [35, 36]. However, this has not been confirmed 
by larger RCTs that compared extremely preterm 
neonates randomized to NCPAP or intubation at 
birth [36, 37].
Nasal intermittent positive pressure ventilation 
(NIPPV) is another approach of NIV in which the 
nasal intermittent positive pressure ventilation is 
given via nasal prongs and creates intermittently 
elevated pharyngeal pressures [38]. Studies on 
NIPPV demonstrated a statistically significant 
benefit for infants extubated to NIPPV compared 
to NCPAP to prevent extubation failure and to 
reduce the frequency of apneas [39]. These benefits 
were associated with a trend towards lower rates of 
chronic lung disease, but did not reach statistical 
significance; that was partly related to small sample 
size of the studies [40].
In a largest retrospective analysis comparing 
synchronized NIPPV to NCPAP use in preterm 
neonates, after controlling for confounding variables, 
use of SNIPPV in the birth-weight category of 500-
750 g was associated with decreased BPD and BPD/
death [41].
Recently high flow nasal cannula (HFNC) is 
emerging as an efficient, better tolerated form of NIV, 
allowing better access to the baby and improving 
nursing. Humidified and optimally warmed 
respiratory gases are given by nasal cannula at flow 
rates between 2 and 8 L/min. Although a growing 
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evidence of the feasibility of HFNC as an alternative 
mode of NIV, its clinical efficacy and safety are still 
insufficiently investigated and therefore insufficient 
data on rate of BPD are available [42]. 
It was demonstrated that the mode of respiratory 
support in the first week of life was correlated with 
the outcome of BPD/death. In a multivariate analysis, 
when compared with endotracheal intubation, 
NIPPV and NCPAP groups were less likely to have 
BPD/death [43]. 
Stem cells
Recent advances in understanding of stem cells 
and their potential to repair damaged organs offer 
the possibility of cell-based treatments for neonatal 
lung injury.
Although there are currently no published clinical 
trials on the use of stem cells in treating or preventing 
BPD, significant progress in our understanding of 
stem cell therapy for BPD has been achieved. Recent 
animal and human studies suggest that damage or 
depletion of stem cells in the developing lung 
likely contributes to the pathogenesis of BPD [44]. 
In experimental models, mesenchimal stem cells 
(MSCs) are the most extensively examined cell type. 
Numerous aspects of neonatal lung injury have been 
ameliorated by the administration of either bone 
marrow-derived or umbelical cord blood-derived 
MSCs. The MSCs exerted their therapeutic effects 
by mitigating lung inflammation, preventing lung 
vascular damage and alveolar growth impairment, 
inhibiting lung fibrosis, and improving exercise 
tolerance [45].
Some studies support the notion that the potential 
mechanisms through which MSCs exert their actions 
are paracrine mediated, and that the therapeutic 
benefit of MSC-conditioning media may surpass 
that of MSCs, alleviating some concerns, such as the 
possibility of tumor formation [46].
No definitive human studies or results have yet 
to show benefits, but preclinical studies are ongoing 
and suggest great promise for future potential 
therapies for BPD [44].
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